Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGG-523 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | AGG-523 1800 mg QD PO (12 capsules) for 28 days |
| B | ACTIVE_COMPARATOR | AGG-523 900 mg BID PO (12 capsules) for 28 days |
| C | PLACEBO_COMPARATOR | Placebo QD PO (12 capsules) for 28 days |
| D | PLACEBO_COMPARATOR | Placebo BID PO (12 capsules) for 28 days |
| Name | Type | Description |
|---|---|---|
| AGG-523 (Aggrecanase Inhibitor) | DRUG | - |
| AGG-523 | DRUG | - |
Inclusion Criteria: * Generally healthy, men or women, at least 55 years old * Osteoarthritis of the knee requiring total knee replacement surgery Exclusion Criteria: * Other types of arthritis, like rheumatoid arthritis * Recent major surgery (in past 3 months) * Recent knee injections (in past ...
AGG-523 is an investigational small molecule being studied for use in osteoarthritis. It has been evaluated in Phase 1 clinical trials involving healthy subjects and patients with osteoarthritis, including those with severe osteoarthritis requiring total knee replacement.
AGG-523 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange.
AGG-523 is in Phase 1 clinical development. It has completed multiple Phase 1 trials, but it is not approved by the FDA and remains an investigational drug.
AGG-523 has been studied in several completed Phase 1 trials, including NCT00380900, NCT00427687, NCT00434785, and NCT00454298. These trials evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects and patients with osteoarthritis.
No alternative names for AGG-523 have been disclosed. It is identified solely by the code name AGG-523 in clinical trial registrations.